Amanta Healthcar
BSE: AMANTA · Pharmaceuticals
Snapshot
Unlock Amanta Healthcar's vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Amanta Healthcare is a pharmaceutical company specialising in the development, manufacturing, and marketing of sterile liquid products. The company focuses on parenteral medications, including fluid therapy, ophthalmics, respiratory care, and irrigation solutions, utilising advanced Aseptic Blow-Fill-Seal and Injection Stretch Blow Moulding technologies.
Business Model
The company generates revenue through the manufacturing and sale of sterile pharmaceutical products and medical devices. It leverages specialised production technologies to serve diverse therapeutic segments within the healthcare sector.
Growth Outlook
Growth is driven by the expansion of its sterile liquid product portfolio and the application of advanced manufacturing technologies across its six therapeutic areas.
Key Risks
- Regulatory Compliance. The company faces stringent regulatory oversight from health authorities regarding the manufacturing standards of sterile pharmaceutical products.
- Operational Risks. Reliance on specialised technologies like Aseptic Blow-Fill-Seal requires continuous maintenance and high-level technical expertise to prevent production disruptions.
- Market Competition. The pharmaceutical sector is highly competitive, with pricing pressures and the constant need for innovation in therapeutic delivery systems.
- Supply Chain Volatility. Fluctuations in the cost and availability of raw materials for sterile manufacturing can impact profit margins.
Start your research today
Unlock AI insights, financials, peers and live data on Amanta Healthcar and 5,000+ companies — free.
Key Metrics
P/E
45.8×
Q1 FY27 · standalone
EV/EBITDA
14.2x
Q1 FY27 · standalone
NET PROFIT MARGIN
4.8%
Q1 FY27 · standalone
Peers · Pharmaceuticals
| Company | Mkt Cap | P/E (TTM) | EV/EBITDA | Rev Gr YoY | EBITDA Mgn | ROE | ROCE | 1Y Return |
|---|---|---|---|---|---|---|---|---|
Amanta HealthcarAMANTA | ₹735 Cr | 45.8× | 14.20 | — | 21.5% | 6.7% | 9.9% | +39.7% |
WanburyWANBURY | ₹814 Cr | 11.4× | 10.33 | 3.6% | 15.2% | 54.9% | 29.2% | -20.6% |
Bafna Pharmaceuticals LimitedBAFNAPH | ₹796 Cr | 115.1× | 46.63 | -3.1% | 12.5% | 8.6% | 10.3% | +119.3% |
Kilitch Drugs (India) LimitedKILITCH | ₹775 Cr | 17.4× | 17.72 | 14.0% | 20.2% | 12.1% | 15.6% | -36.5% |
Zim LaboratoriesZIMLAB | ₹715 Cr | 167.1× | 20.79 | 7.6% | 9.9% | 1.3% | 5.7% | +91.2% |
Valiant Laboratories LimitedVALIANTLAB | ₹658 Cr | 42.4× | 19.55 | 89.6% | 11.7% | 5.9% | 8.0% | +50.1% |
As of Q1 FY27
Financials
Amanta Healthcar
BSE: AMANTA · Pharmaceuticals
Snapshot
Unlock Amanta Healthcar's vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Amanta Healthcare is a pharmaceutical company specialising in the development, manufacturing, and marketing of sterile liquid products. The company focuses on parenteral medications, including fluid therapy, ophthalmics, respiratory care, and irrigation solutions, utilising advanced Aseptic Blow-Fill-Seal and Injection Stretch Blow Moulding technologies.
Business Model
The company generates revenue through the manufacturing and sale of sterile pharmaceutical products and medical devices. It leverages specialised production technologies to serve diverse therapeutic segments within the healthcare sector.
Growth Outlook
Growth is driven by the expansion of its sterile liquid product portfolio and the application of advanced manufacturing technologies across its six therapeutic areas.
Key Risks
- Regulatory Compliance. The company faces stringent regulatory oversight from health authorities regarding the manufacturing standards of sterile pharmaceutical products.
- Operational Risks. Reliance on specialised technologies like Aseptic Blow-Fill-Seal requires continuous maintenance and high-level technical expertise to prevent production disruptions.
- Market Competition. The pharmaceutical sector is highly competitive, with pricing pressures and the constant need for innovation in therapeutic delivery systems.
- Supply Chain Volatility. Fluctuations in the cost and availability of raw materials for sterile manufacturing can impact profit margins.
Start your research today
Unlock AI insights, financials, peers and live data on Amanta Healthcar and 5,000+ companies — free.
Key Metrics
P/E
45.8x
Q1 FY27 · standalone
EV/EBITDA
14.2x
Q1 FY27 · standalone
NET PROFIT MARGIN
4.8%
Q1 FY27 · standalone
Peers · Pharmaceuticals
As of Q1 FY27